EU

Showing 15 posts of 252 posts found.

allergan

Allergan says its double chin correction therapy Belkyra gets positive opinion from Swedish regulators

July 4, 2016
Research and Development, Sales and Marketing Allergan, Belkyra, Botox, EU, Sweden, double chin, drug trial

Botox maker Allergan (NYSE: AGN) said it has received a positive opinion from the Swedish Medical Products Agency for its …

roche

Roche secures EU approval for Gazyvaro in new lymphoma indication

June 16, 2016
Research and Development, Sales and Marketing EU, Gazyvaro, Roche, follicular lymphoma

Roche (SIX: RO) has announced that the European Commission has approved Gazyvaro (obinutuzumab), in combination with bendamustine chemotherapy, in patients …

actelion_logo

Actelion says blood pressure drug Uptravi now available in Germany

June 15, 2016
Research and Development, Sales and Marketing Actelion, EU, blood pressure, product launch

Actelion (SIX: ATLN) said its high blood pressure drug Uptravi (selexipag) is now available in Germany.  The European Commission granted …

humira_abbott__4

EU ombudsman calls for more transparency from AbbVie on Humira

June 10, 2016
Medical Communications, Research and Development AbbVie, EMA, EU, Humira, ombudsman

Abbvie continues to withhold details of clinical trials involving the world’s top-selling prescription medicine, Humira (adalimumab), according to the European …

gsk_l_rgb

GSK’s gene therapy Strimvelis gets European regulatory nod

June 1, 2016
Research and Development, Sales and Marketing EU, European Commission, GlaxoSmithKline, Strimvelis, gene therapy, regulation

UK drugmaker GlaxoSmithKline (LSE: GSK) said its gene therapy Strimvelis has secured backing from the European regulators. The European Commission …

janssen_latest_logo_on_sign

Genmab receives milestone payment for first Darzalex sale in Europe

May 31, 2016
Manufacturing and Production, Sales and Marketing EU, FDA, Janssen, commercial, commercialised, daratumumab, darzalex, genman, multiple myeloma, sale, sales

Genmab (NASDAQ: GEN) has announced that the company is set to receive a milestone payment of $30 million from its …

lab

EU approves Idelvion for haemophilia B treatment

May 13, 2016
Medical Communications, Research and Development CSL, EU, Idelvion, approval, haemophilia B

The European Commission has approved Idelvion, coagulation Factor IX (recombinant) for the treatment and prophylaxis of bleeding in patients with …

Multiple myeloma treatment from BMS and AbbVie scores EU approval

May 12, 2016
Research and Development, Sales and Marketing AbbVie, BMS, EMA, EU, Empliciti, approval, bristl-myers squibb, elotuzumab, multiple myeloma

Bristol-Myers Squibb (NYSE: BMY) and AbbVie (NYSE: ABBV) have announced that the European Commission has approved Empliciti (elotuzumab) for the …

abpi_reception_right

UK pharma would benefit by remaining in EU, says ABPI

May 9, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Andrew Witty, EU, brexit, letter, observer, pascal soriot, remain, stay

With the EU vote approaching, the Association of the British Pharmaceutical Industry (ABPI) has brought together 93 signatories, including the …

eli_lilly_logo

Eli Lilly gets European marketing authorisation for psoriasis drug

April 26, 2016
EC, EU, Eli Lilly, drug trial, psoriasis, regulation

US pharma firm Eli Lilly and Co (NYSE: LLY) on Tuesday said the European Commission backed marketing authorisation for its …

gilead-sciences

EU grants approval for Gilead’s HIV treatment Descovy

April 26, 2016
Manufacturing and Production, Research and Development EU, HIV, approval, descovy, taf

Gilead Sciences (NASDAQ: GILD) has announced that the fixed-dose combination HIV treatment, Descovy (emtricitabine, tenofovir alafenamide), has been granted marketing …

opdivo_1

Bristol-Myers Squibb cancer immunotherapy Opdivo approved in EU

April 13, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, EU, NICE, approval, immunotherapy, opdivo

Bristol-Myers Squibb has announced that its potentially life-extending cancer immunotherapy, Opdivo (nivolumab), has been approved by the European Commission to …

Novartis receives EU approval for blood disorder treatment in children

April 7, 2016
Research and Development, Sales and Marketing EMA, EU, ITP, Novartis, Revolade, approval, blood disorder, children, chronic itp

Novartis (NYSE: NVS) has announced that Revolade (eltrombopag) has been approved in the EU for use in paediatric patients aged …

shutterstock_212432119

Leo Pharma gets EU scientific approval for its psoriasis drug Enstilar

March 21, 2016
Business Services, Research and Development, Sales and Marketing EU, Enstilar, LEO Pharma, psoriasis vulgaris

Leo Pharma on Monday said its drug to treat inflammatory skin condition has received scientific approval in the European Union. …

The Gateway to Local Adoption Series

Latest content